(MedPage Today) — A fourth of patients with advanced melanoma that had progressed on anti-PD-(L)1 therapy responded to an investigational immune-system stimulant plus pembrolizumab (Keytruda), according to a small phase II study.
Ten of 40 patients…
Source link : https://www.medpagetoday.com/oncology/skincancer/116533
Author :
Publish date : 2025-07-16 21:40:00
Copyright for syndicated content belongs to the linked Source.
